Welcome to our dedicated page for QuidelOrtho SEC filings (Ticker: QDEL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on QuidelOrtho's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into QuidelOrtho's regulatory disclosures and financial reporting.
QuidelOrtho Corp director John R. Chiminski reported routine equity compensation activity. On May 29, 2026, restricted stock units vested and were converted into 6,829 shares of Common Stock, reflecting a previously reported award.
Each restricted stock unit represented one share of QuidelOrtho common stock, and the units vested on May 29, 2026. After this grant and corresponding RSU release, Chiminski directly holds 9,352 shares of QuidelOrtho Common Stock, with no remaining position reported in the related RSUs.
QuidelOrtho Corp director R. Scott Huennekens reported a routine equity compensation event. He acquired 6,829 shares of common stock at a stated price of $0.0000 per share through the release of previously granted restricted stock units. These restricted stock units vested on May 29, 2026 and each unit converted into one share of common stock. Following this vesting and conversion, he directly holds 9,352 shares of QuidelOrtho common stock. The filing shows no open-market purchases or sales, only the vesting and exercise of an equity award.
QuidelOrtho Corp director Joseph D. Wilkins Jr. reported equity compensation activity involving 6,829 shares. He received 6,829 shares of common stock on May 29, 2026 through the release of previously granted restricted stock units, with no sales reported. Following these transactions, he directly owns 18,705 shares of QuidelOrtho common stock. The filing also shows the corresponding exercise of 6,829 restricted stock units into common shares, with no remaining units from this grant after vesting.
QuidelOrtho Corp director Ann D. Rhoads reported equity compensation activity involving restricted stock units. She received 6,829 shares of Common Stock at no cost, related to previously reported restricted stock units. These restricted stock units, each representing one share of common stock, vested on May 29, 2026 and were exercised into common shares the same day. Following these transactions, she holds 23,257 shares of QuidelOrtho common stock directly, with no remaining position in the exercised restricted stock units.
QuidelOrtho Corp director Michael Edward L. received 6,829 shares of Common Stock as a stock award on May 29, 2026, when previously granted restricted stock units vested. These RSUs were exercised into Common Stock, bringing his direct holdings to 28,181 shares, with no open-market buying or selling.
QuidelOrtho Corp director Evelyn S. Dilsaver reported an equity award and related vesting of restricted stock units. On May 29, 2026, she acquired 6,829 shares of common stock at no cost through the release of previously reported restricted stock units. Each unit converted into one share of common stock when the units vested on May 29, 2026. Following these transactions, she directly holds 17,453 shares of QuidelOrtho common stock, and the reported restricted stock unit grant has been fully exercised.
QuidelOrtho Corp director Ann D. Rhoads reported routine equity compensation activity. She received a total of 1,407 shares of common stock on May 22, 2026 through the release of previously reported restricted stock units.
Footnotes state these restricted stock units each convert into one share of common stock and that their release was deferred under QuidelOrtho’s deferred compensation program for participating non-employee directors, occurring according to her elected deferral schedule. The filing shows no open‑market purchases or sales, only grants and conversions of equity awards.
QuidelOrtho Corp President and CEO Brian J. Blaser reported routine equity compensation activity. On May 15, 20,759 restricted stock units converted into an equal number of common shares, reflecting a scheduled vesting.
To cover tax obligations from this vesting, 10,252 common shares were withheld at $10.32 per share, a tax-withholding disposition rather than an open-market sale. Following these transactions, he holds 35,649 common shares directly and 40,073 common shares indirectly through a trust. Footnotes note that 20,759 shares vested on each of May 15, 2025 and May 15, 2026, with another 20,759 scheduled to vest on May 15, 2027.
FMR LLC amends a Schedule 13G to report beneficial ownership of 7,852,321.81 shares of Common Stock of QUIDELORTHO CORP, representing 11.5% of the class.
The filing states FMR LLC has sole dispositive power over 7,852,321.81 shares and sole voting power of 7,850,418.00 shares. Abigail P. Johnson is listed with sole dispositive power of 7,852,321.81 shares. Signatures indicate authority under a Power of Attorney effective April 13, 2026, with the amendment dated April 30, 2026.
QuidelOrtho Corp ownership update: Invesco Ltd. reported beneficial ownership of 3,117,469 shares of QuidelOrtho Common Stock, representing 4.6% of the class as of 03/31/2026. The filing states these shares are held of record by clients of Invesco Ltd., and Invesco reports sole voting power over 3,097,919 shares and sole dispositive power over 3,117,469 shares. The schedule is an amendment filed by the parent holding company and lists Invesco Advisers, Inc. and Invesco Capital Management LLC as relevant subsidiaries.